This article discusses a recent publication examining pharmacy access across Minnesota and explores the complex factors contributing to threatened community health access across the US.
|Videos|September 12, 2015
How Socioeconomic Factors Affect Adherence
Eric A Wright, PharmD, MPH, investigator I for Geisinger Health Research and associate professor at Wilkes University, discusses how socioeconomic factors affect adherence.
Advertisement
Eric A Wright, PharmD, MPH, investigator I for Geisinger Health Research and associate professor at Wilkes University, discusses how socioeconomic factors affect adherence.
This video was recorded at the 2015 NACDS Total Store Expo.
Advertisement
Related to this article
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
With nearly 8 in 10 older adults misusing at least 1 OTC product, clearer counseling and labels could close the gap.
Contraceptive access gaps driven by federal rollbacks, provider shortages, and stalled state legislation could be narrowed by letting trained pharmacists prescribe birth control independently.
Cancer diagnoses among civilians exposed to 9/11 dust keep rising, with strained health programs struggling to meet growing needs.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
2
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
3
FDA Reduces Monitoring Time for First Two Tarlatamab Doses
4
Radioligand Therapy Doesn’t Need to Be Risk-Free—It Needs to Be Worth It
5